Publications

Introduction

Recently, LNP-based mRNA vaccines have gained widespread attention and offer an attractive modality for personalized cancer therapies. However, inducing an effective anti-tumor response often requires the induction of a T cell response breaking self-tolerance mechanisms, a challenge for current therapies. 

Here, we developed new lipid nanoparticle (LNP) formulations which can be utilized for therapeutic mRNA/LNP cancer vaccines. Utilizing an in vivo screening model identifying LNP formulations capable of breaking self-tolerance allows the selection of LNP candidates with superior anti-tumor efficacy. In the well characterized mouse syngeneic colorectal cancer (CRC) model expressing model glycoprotein antigens from lymphocytic choriomeningitis virus (LCMV, MC38gp), intramuscular administration of this new LNP formulation as a monotherapy in a therapeutic setting after tumor inoculation significantly delayed tumor growth and cleared tumors in 50% of treated mice. 

The data suggests the possible applicability of our next generation LNP formulations for the development of effective therapeutic mRNA cancer vaccines for multiple solid tumors.

Read Full Article Here